Format

Send to

Choose Destination
FEBS Lett. 2011 Dec 1;585(23):3699-709. doi: 10.1016/j.febslet.2011.03.023. Epub 2011 Mar 21.

Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.

Author information

1
Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan.

Abstract

Interleukin (IL)-6 is a cytokine with multiple biological activities. It contributes to host defense against pathogens, whereas accelerated production of IL-6 plays a significant pathological role in various diseases. Clinical trials have demonstrated the efficacy of tocilizumab, a humanized anti-IL-6 receptor antibody, for patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis, leading to approval of this innovative drug for the treatment of these diseases. Since IL-6 has been demonstrated to play a significant role in the development of various other autoimmune and inflammatory diseases, tocilizumab can be expected to become a novel drug for such diseases as well.

PMID:
21419125
DOI:
10.1016/j.febslet.2011.03.023
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center